In Focus
Compensatory Pathways in Oncogenic Kinase Signaling and Resistance to Targeted Therapies: Six Degrees of Separation
L. Trusolino and A. Bertotti

REVIEW
Cancer Cell Metabolism: One Hallmark, Many Faces
J.R. Cantor and D.M. Sabatini

RESEARCH BRIEF
Comparative Genomic Analysis of Esophageal Adenocarcinoma and Squamous Cell Carcinoma

Précis:
Exomic sequencing of esophageal cancer subtypes identified geographic disparities and differences in mutation frequencies, particularly of NOTCH genes.

RESEARCH ARTICLES
VEGF/Neuropilin-2 Regulation of Bmi-1 and Consequent Repression of IGF-IR Define a Novel Mechanism of Aggressive Prostate Cancer

Précis:
NRP2 signaling inhibits IGF-IR expression via BMI-1 activity in advanced PTEN-null prostate cancer.

In The Spotlight
Histology, Anatomy, or Geography? Exome Sequencing Begins to Delineate Somatic Mutational Differences in Esophageal Cancer
E.A. Collisson and R.J. Cho

Commentary on Agrawal et al., p. 899

Resiliency of Lung Cancers to EGFR Inhibitor Treatment Unveiled, Offering Opportunities to Divide and Conquer EGFR Inhibitor Resistance
C.M. Blakely and T.G. Bivona

Commentary on Erkan et al., p. 934, and Tokezawa et al., p. 922
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFR<sup>T790M</sup> Mutation ................. 922
Précis: Increased HER2 expression confers resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancers with EGFR mutations.

Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors ................. 934
Précis: Acquired resistance to EGFR inhibitors can occur through aberrant activation of ERK signaling via MAPK1 amplification or downregulation of ERK negative regulators.

Correction


For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org. Online-only News stories include the following:

• Setting the Stage for Cancer Startups
• NCI Trials Program Looks for Net Gains
• Zaltrap Approved for Metastatic Colorectal Cancer
• UPenn, Novartis Team Up on Adoptive T-Cells
• Genomics Venture Sets Sights on Clinical Trials
• More NIH Grants to Undergo Second Review